JP Morgan Chase
STOK icon

JP Morgan Chase’s Stoke Therapeutics STOK Stock Holding History

JP Morgan Chase’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.48M Sell
259,352
-6,121
-2% -$196K ﹤0.01% 2959
2026
Q1 		$8.43M Sell
265,473
-12,457
-4% -$409K ﹤0.01% 2838
2025
Q4 		$8.82M Buy
277,930
+253,554
+1,040% +$7.62M ﹤0.01% 2798
2025
Q3 		$573K Sell
24,376
-1,279
-5% -$21.9K ﹤0.01% 4936
2025
Q2 		$291K Buy
25,655
+5,398
+27% +$51.3K ﹤0.01% 5049
2025
Q1 		$135K Buy
20,257
+293
+1% +$2.73K ﹤0.01% 5420
2024
Q4 		$220K Buy
19,964
+4,512
+29% +$55.4K ﹤0.01% 5430
2024
Q3 		$190K Buy
15,452
+199
+1% +$2.82K ﹤0.01% 5426
2024
Q2 		$206K Buy
15,253
+4,309
+39% +$58.2K ﹤0.01% 5154
2024
Q1 		$148K Sell
10,944
-7,189
-40% -$43.6K ﹤0.01% 5501
2023
Q4 		$95.4K Sell
18,133
-8,397
-32% -$35.9K ﹤0.01% 5754
2023
Q3 		$105K Buy
26,530
+3,363
+15% +$22.1K ﹤0.01% 5448
2023
Q2 		$246K Sell
23,167
-91,300
-80% -$971K ﹤0.01% 4958
2023
Q1 		$954K Buy
114,467
+90,608
+380% +$817K ﹤0.01% 4074
2022
Q4 		$220K Buy
23,859
+291
+1% +$3.03K ﹤0.01% 4988
2022
Q3 		$302K Buy
23,568
+1,070
+5% +$17.1K ﹤0.01% 4747
2022
Q2 		$297K Buy
22,498
+2,890
+15% +$43.9K ﹤0.01% 4864
2022
Q1 		$412K Buy
19,608
+3,374
+21% +$67.6K ﹤0.01% 4826
2021
Q4 		$390K Buy
16,234
+1,506
+10% +$35.9K ﹤0.01% 4992
2021
Q3 		$375K Buy
14,728
+983
+7% +$27.4K ﹤0.01% 4889
2021
Q2 		$463K Buy
13,745
+4,156
+43% +$147K ﹤0.01% 4748
2021
Q1 		$373K Buy
9,589
+3,573
+59% +$203K ﹤0.01% 4855
2020
Q4 		$373K Buy
6,016
+1,462
+32% +$67K ﹤0.01% 4539
2020
Q3 		$156K Sell
4,554
-137
-3% -$3.91K ﹤0.01% 4482
2020
Q2 		$112K Sell
4,691
-814
-15% -$19.3K ﹤0.01% 4524
2020
Q1 		$126K Buy
5,505
+2,486
+82% +$61.4K ﹤0.01% 4452
2019
Q4 		$86K Buy
3,019
+18
+0.6% +$453 ﹤0.01% 4955
2019
Q3 		$64K Buy
+3,001
New +$83.7K ﹤0.01% 5065

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's STOK Position: Q2 2026 in Review

JP Morgan Chase reduced its Stoke Therapeutics (STOK) stake by 2.3% in Q2 2026, selling an estimated $196K and leaving 259,352 shares worth $8.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

JP Morgan Chase first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. The position peaked at $8.82M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • JP Morgan Chase held 259,352 shares of Stoke Therapeutics worth $8.48M as of Q2 2026.
  • JP Morgan Chase sold 6,121 Stoke Therapeutics shares in Q2 2026, an estimated $196K.
  • Stoke Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2959 holding.
  • JP Morgan Chase first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's Stoke Therapeutics position peaked at $8.82M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.